Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
Weight-loss drugs have been surging in popularity over the past year. Even Novo Nordisk's Ozempic, which isn't approved to treat weight loss, has made for a hot trend on social media, with people showing off their results from using the diabetes drug.
And now, there could soon be another weight-loss treatment that consumers may be able to use, and it's from (NYSE: PFE).
A peer-reviewed study has recently come out on Pfizer's weight-loss treatment, danuglipron. And the study, which is based on phase 2 trial data, is encouraging. Patients with type 2 diabetes who took the pill twice daily lost an average of 10 pounds during a period of 16 weeks.
Source Fool.com
Pfizer Inc. Stock
€28.43
0.280%
With 28 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a positive potential of 44.24% for Pfizer Inc. compared to the current price of 28.43 €.
